ReviewNeuroRx : the journal of the American Society for Experimental NeuroTherapeutics2005
Neuroimaging biomarkers for clinical trials of disease-modifying therapies in Alzheimer's disease.
Review in NeuroRx : the journal of the American Society for Experimental NeuroTherapeutics, 2005. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 58 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
58 citing papers in PubMed, 2 syntheses or guidelines pooled it.
- Resting State Abnormalities of the Default Mode Network in Mild Cognitive Impairment: A Systematic Review and Meta-Analysis.Journal of Alzheimer's disease : JAD · 2019Pooled it
- Multimodal Voxel-Based Meta-Analysis of White Matter Abnormalities in Alzheimer's Disease.Journal of Alzheimer's disease : JAD · 2015Pooled it
- Longitudinal multimodal imaging in mild to moderate Alzheimer disease: a pilot study with memantine.Journal of neurology, neurosurgery, and psychiatry · 2008Trial
- A radiomics model predicts progression from mild cognitive impairment to alzheimer's disease using structural MRI.Scientific reports · 2025Article
- Increasing hub disruption parallels dementia severity in autosomal dominant Alzheimer's disease.Network neuroscience (Cambridge, Mass.) · 2024Article
- Fractal Analysis in Neurodegenerative Diseases.Advances in neurobiology · 2024Article
- Increasing hub disruption parallels dementia severity in autosomal dominant Alzheimer disease.bioRxiv : the preprint server for biology · 2023Article
- DWI-based MR thermometry: could it discriminate Alzheimer's disease from mild cognitive impairment and healthy subjects?Neuroradiology · 2022Article
- A novel deep learning based hippocampus subfield segmentation method.Scientific reports · 2022Article
- How to Arrange Follow-Up Time-Intervals for Longitudinal Brain MRI Studies in Neurodegenerative Diseases.Frontiers in neuroscience · 2021Article
- Altered Homotopic Functional Connectivity Within White Matter in the Early Stages of Alzheimer's Disease.Frontiers in neuroscience · 2021Article
- A Simulation Toolkit for Testing the Sensitivity and Accuracy of Corticometry Pipelines.Frontiers in neuroinformatics · 2021Article
- Prediction of the progression from mild cognitive impairment to Alzheimer's disease using a radiomics-integrated model.Therapeutic advances in neurological disorders · 2021Article
- Article
- Functional Integration and Segregation in Multiplex Brain Networks for Alzheimer's Disease.Frontiers in neuroscience · 2020Article
- MR-assisted PET motion correction in simultaneous PET/MRI studies of dementia subjects.Journal of magnetic resonance imaging : JMRI · 2018Article
- Longitudinal Progression Markers of Parkinson's Disease: Current View on Structural Imaging.Current neurology and neuroscience reports · 2018Review
- Effects of pharmacological and nonpharmacological treatments on brain functional magnetic resonance imaging in Alzheimer's disease and mild cognitive impairment: a critical review.Alzheimer's research & therapy · 2018Review
- Test-retest variability of resting-state networks in healthy aging and prodromal Alzheimer's disease.NeuroImage. Clinical · 2018Article
- Multimodal PET Imaging of Amyloid and Tau Pathology in Alzheimer Disease and Non-Alzheimer Disease Dementias.PET clinics · 2017Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
Abstract
The pathophysiologic process leading to neurodegeneration in Alzheimer's disease (AD) is thought to begin long before clinical symptoms develop. Existing therapeutics for AD improve symptoms, but increasing efforts are being directed toward the development of therapies to impede the pathologic progression of the disease. Although these medications must ultimately demonstrate efficacy in slowing clinical decline, there is a critical need for biomarkers that will indicate whether a candidate disease-modifying therapeutic agent is actually altering the underlying degenerative process. A number of in vivo neuroimaging techniques, which can reliably and noninvasively assess aspects of neuroanatomy, chemistry, physiology, and pathology, hold promise as biomarkers. These neuroimaging measures appear to relate closely to neuropathological and clinical data, such as rate of cognitive decline and risk of future decline. As this work has matured, it has become clear that neuroimaging measures may serve a variety of potential roles in clinical trials of candidate neurotherapeutic agents for AD, depending in part on the question of interest and phase of drug development. In this article, we review data related to the range of neuroimaging biomarkers of Alzheimer's disease and consider potential applications of these techniques to clinical trials, particularly with respect to the monitoring of disease progression in trials of disease-modifying therapies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.